Yet another gene therapy spinoff from Nationwide Children's Hospital has been acquired for $100 million. Celenex is developing a treatment for Batten Disease, a rare, fatal neurological condition that causes blindness and progressive loss of speech and movement. Children who inherit it typically don't live past age 12. The startup was acquired by Amicus Therapeutics Inc., a Cranbury, New Jersey-based biotechnology company that focuses on rare metabolic disorders. Columbus-based Rev1 Ventures,…